PTEN Loss

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma1
PTEN Loss	Everolimus	Predictive	B	Supports Resistance	4	accepted	EID644 PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer. PMID 23989949 · Seront et al., 2013 · Open in CIViC	civic
Gastric Adenocarcinoma1
PTEN Loss	Lapatinib + TrastuzumabSubstitutes	Predictive	B	Supports Resistance	2	accepted	EID864 In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) … (full text at CIViC) PMID 25300346 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Bladder Carcinoma1

PTEN Loss

Everolimus

Predictive

Supports Resistance

accepted

EID644

PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.

PMID 23989949 · Seront et al., 2013 · Open in CIViC

civic

Gastric Adenocarcinoma1

PTEN Loss

Lapatinib + TrastuzumabSubstitutes

Predictive

Supports Resistance

accepted

EID864

In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) … (full text at CIViC)

PMID 25300346 ·

Gastric Carcinoma1
PTEN Loss	Chemotherapy	Predictive	B	Supports Resistance	2	accepted	EID1493 Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-… (full text at CIViC) PMID 15900596 · Oki et al., 2005 · Open in CIViC	civic

Gastric Carcinoma1

PTEN Loss

Chemotherapy

Predictive

Supports Resistance

accepted

EID1493

Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-… (full text at CIViC)

PMID 15900596 · Oki et al., 2005 · Open in CIViC

civic

HER2-Positive Breast Carcinoma11
PTEN Loss	Dactolisib + Lapatinib + TrastuzumabCombination	Predictive	D	Supports Sensitivity Response	2	submitted	EID8280 In a preclinical study, efficacy of NVP-BEZ235 (dactolisib), lapatinib, and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induc… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC	civic
PTEN Loss	Everolimus	Predictive	B	Supports Sensitivity Response	4	accepted	EID1297 Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger seque… (full text at CIViC) PMID 27091708 · André et al., 2016 · Open in CIViC	civic
PTEN Loss	PI-103	Predictive	D	Supports Sensitivity Response	1	accepted	EID8012 As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
PTEN Loss	PI3Ka/Di	Predictive	D	Supports Resistance	1	accepted	EID8022 As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
PTEN Loss	Pictilisib	Predictive	D	Supports Sensitivity Response	3	accepted	EID2045 This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
PTEN Loss	Trastuzumab	Predictive	B	Supports Resistance	3	accepted	EID1385 A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and… (full text at CIViC) PMID 20813970 · Esteva et al., 2010 · Open in CIViC	civic
PTEN Loss	Trastuzumab	Predictive	B	Does Not Support Resistance	3	accepted	EID1386 While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second o… (full text at CIViC) PMID 20813970 · Esteva et al., 2010 · Open in CIViC	civic
PTEN Loss	Trastuzumab	Predictive	B	Supports Resistance	2	accepted	EID2035 In a retrospective study of 111 HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with shorter survival as measured … (full text at CIViC) PMID 21594665 · Razis et al., 2011 · Open in CIViC	civic
PTEN Loss	Trastuzumab	Predictive	D	Supports Resistance	2	accepted	EID1383 A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in… (full text at CIViC) PMID 17936563 · Berns et al., 2007 · Open in CIViC	civic
PTEN Loss	Trastuzumab Emtansine	Predictive	B	Does Not Support Resistance	3	accepted	EID8706 In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors had decreased, slightly decreased, or absent PTEN expression (assessed by IHC) treated with ad… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC	civic
PTEN Loss	PI3K/BET Inhibitor LY294002 + TrastuzumabCombination	Predictive	D	Supports Sensitivity Response	3	accepted	EID1455 Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition,… (full text at CIViC) PMID 15324695 · Nagata et al., 2004 · Open in CIViC	civic

HER2-Positive Breast Carcinoma11

PTEN Loss

Dactolisib + Lapatinib + TrastuzumabCombination

Predictive

Supports Sensitivity Response

submitted

EID8280

In a preclinical study, efficacy of NVP-BEZ235 (dactolisib), lapatinib, and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induc… (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC

civic

PTEN Loss

Everolimus

Predictive

Supports Sensitivity Response

accepted

EID1297

Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger seque… (full text at CIViC)

PMID 27091708 · André et al., 2016 · Open in CIViC

civic

PTEN Loss

PI-103

Predictive

Supports Sensitivity Response

accepted

EID8012

As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, … (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

civic

PTEN Loss

PI3Ka/Di

Predictive

Supports Resistance

accepted

EID8022

As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

civic

PTEN Loss

Pictilisib

Predictive

Supports Sensitivity Response

accepted

EID2045

This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more … (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

civic

PTEN Loss

Trastuzumab

Predictive

Supports Resistance

accepted

EID1385

A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and… (full text at CIViC)

PMID 20813970 · Esteva et al., 2010 · Open in CIViC

civic

PTEN Loss

Trastuzumab

Predictive

Does Not Support Resistance

accepted

EID1386

While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second o… (full text at CIViC)

PMID 20813970 · Esteva et al., 2010 · Open in CIViC

civic

PTEN Loss

Trastuzumab

Predictive

Supports Resistance

accepted

EID2035

In a retrospective study of 111 HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with shorter survival as measured … (full text at CIViC)

PMID 21594665 · Razis et al., 2011 · Open in CIViC

civic

PTEN Loss

Trastuzumab

Predictive

Supports Resistance

accepted

EID1383

A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in… (full text at CIViC)

PMID 17936563 · Berns et al., 2007 · Open in CIViC

civic

PTEN Loss

Trastuzumab Emtansine

Predictive

Does Not Support Resistance

accepted

EID8706

In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors had decreased, slightly decreased, or absent PTEN expression (assessed by IHC) treated with ad… (full text at CIViC)

PMID 26920887 · Baselga et al., 2016 · Open in CIViC

civic

PTEN Loss

PI3K/BET Inhibitor LY294002 + TrastuzumabCombination

Predictive

Supports Sensitivity Response

accepted

EID1455

Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition,… (full text at CIViC)

PMID 15324695 · Nagata et al., 2004 · Open in CIViC

civic

Malignant Breast Neoplasm7
PTEN Loss	Alpelisib	Predictive	D	Supports Resistance	4	accepted	EID716 A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation. After partial response for 9.5 months, resistance developed. Sequencing in this and other patients … (full text at CIViC) PMID 25409150 · Juric et al., 2015 · Open in CIViC	civic
PTEN Loss	Everolimus + MTOR Kinase Inhibitor PP242Substitutes	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID1611 In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation w… (full text at CIViC) PMID 21358673 · Weigelt et al., 2011 · Open in CIViC	civic
PTEN Loss	PI3Ka/Di	Predictive	D	Supports Resistance	1	submitted	EID8021 As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
PTEN Loss	PI3Kbeta Inhibitor AZD8186	Predictive	D	Supports Sensitivity Response	2	accepted	EID711 Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency. PMID 25398829 · Hancox et al., 2015 · Open in CIViC	civic
PTEN Loss	Pictilisib	Predictive	D	Does Not Support Sensitivity Response	2	accepted	EID2074 This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
PTEN Loss	Trastuzumab	Predictive	B	Supports Resistance	1	accepted	EID645 PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free sur… (full text at CIViC) PMID 24387334 · Dillon et al., 2014 · Open in CIViC	civic
PTEN Loss	Trastuzumab	Predictive	B	Supports Resistance	2	accepted	EID2043 In a retrospective study of 182 metastatic breast cancer patients of mixed HER2 status treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with a higher risk of death… (full text at CIViC) PMID 21594665 · Razis et al., 2011 · Open in CIViC	civic

Malignant Breast Neoplasm7

PTEN Loss

Alpelisib

Predictive

Supports Resistance

accepted

EID716

A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation. After partial response for 9.5 months, resistance developed. Sequencing in this and other patients … (full text at CIViC)

PMID 25409150 · Juric et al., 2015 · Open in CIViC

civic

PTEN Loss

Everolimus + MTOR Kinase Inhibitor PP242Substitutes

Predictive

Does Not Support Sensitivity Response

accepted

EID1611

In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation w… (full text at CIViC)

PMID 21358673 · Weigelt et al., 2011 · Open in CIViC

civic

PTEN Loss

PI3Ka/Di

Predictive

Supports Resistance

submitted

EID8021

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

civic

PTEN Loss

PI3Kbeta Inhibitor AZD8186

Predictive

Supports Sensitivity Response

accepted

EID711

Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency.

PMID 25398829 · Hancox et al., 2015 · Open in CIViC

civic

PTEN Loss

Pictilisib

Predictive

Does Not Support Sensitivity Response

accepted

EID2074

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

civic

PTEN Loss

Trastuzumab

Predictive

Supports Resistance

accepted

EID645

PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free sur… (full text at CIViC)

PMID 24387334 · Dillon et al., 2014 · Open in CIViC

civic

PTEN Loss

Trastuzumab

Predictive

Supports Resistance

accepted

EID2043

In a retrospective study of 182 metastatic breast cancer patients of mixed HER2 status treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with a higher risk of death… (full text at CIViC)

PMID 21594665 · Razis et al., 2011 · Open in CIViC

civic

Malignant Colorectal Neoplasm3
PTEN Loss	Cetuximab	Predictive	B	Supports Resistance	3	accepted	EID506 In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response. PMID 21163703 · De Roock et al., 2011 · Open in CIViC	civic
PTEN Loss	Cetuximab + PanitumumabSubstitutes	Predictive	B	Supports Resistance	3	accepted	EID6315 In this study, 81 metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). Multivariate analysis demonstrated a s… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC	civic
PTEN Loss	Cetuximab + PanitumumabSubstitutes	Predictive	B	Does Not Support Resistance	1	submitted	EID6361 In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PTEN protein expression… (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC	civic

Malignant Colorectal Neoplasm3

PTEN Loss

Cetuximab

Predictive

Supports Resistance

accepted

EID506

In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response.

PMID 21163703 · De Roock et al., 2011 · Open in CIViC

civic

PTEN Loss

Cetuximab + PanitumumabSubstitutes

Predictive

Supports Resistance

accepted

EID6315

In this study, 81 metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). Multivariate analysis demonstrated a s… (full text at CIViC)

PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC

civic

PTEN Loss

Cetuximab + PanitumumabSubstitutes

Predictive

Does Not Support Resistance

submitted

EID6361

In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PTEN protein expression… (full text at CIViC)

PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC

civic

Malignant Endometrial Neoplasm2
PTEN Loss	Temsirolimus	Predictive	D	Supports Sensitivity Response	3	accepted	EID1614 A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression. Cell lines were assessed … (full text at CIViC) PMID 23674493 · Weigelt et al., 2013 · Open in CIViC	civic
PTEN Loss	Ridaforolimus + TemsirolimusSubstitutes	Predictive	B	Does Not Support Resistance	3	accepted	EID893 94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, inc… (full text at CIViC) PMID 24166148 · Mackay et al., 2014 · Open in CIViC	civic

Malignant Endometrial Neoplasm2

PTEN Loss

Temsirolimus

Predictive

Supports Sensitivity Response

accepted

EID1614

A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression. Cell lines were assessed … (full text at CIViC)

PMID 23674493 · Weigelt et al., 2013 · Open in CIViC

civic

PTEN Loss

Ridaforolimus + TemsirolimusSubstitutes

Predictive

Does Not Support Resistance

accepted

EID893

94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, inc… (full text at CIViC)

PMID 24166148 · Mackay et al., 2014 · Open in CIViC

civic

Malignant Gastric Neoplasm3
PIK3CA E542K AND PTEN Loss	Capivasertib	Predictive	D	Supports Sensitivity Response	2	submitted	EID11063 In a panel of 20 gastric cancer cell lines, the line that showed greatest sensitivity to AZD5363 in MTS cell proliferation assay contained both PIK3CA E542K and PTEN Loss. PMID 24088382 · Li et al., 2013 · Open in CIViC	civic
PTEN Loss	Capivasertib + DocetaxelCombination	Predictive	D	Supports Sensitivity Response	1	accepted	EID1500 A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the … (full text at CIViC) PMID 24088382 · Li et al., 2013 · Open in CIViC	civic
PTEN Loss	Docetaxel	Predictive	D	Supports Resistance	2	accepted	EID11064 SGC020 was a gastric PDGCX mouse model established from a gastric cancer patient, with a PTEN exon 2-6 gene deletion resulting in undetectable PTEN protein expression. The chemotherapy Taxotere was gi… (full text at CIViC) PMID 24088382 · Li et al., 2013 · Open in CIViC	civic

Malignant Gastric Neoplasm3

PIK3CA E542K AND PTEN Loss

Capivasertib

Predictive

Supports Sensitivity Response

submitted

EID11063

In a panel of 20 gastric cancer cell lines, the line that showed greatest sensitivity to AZD5363 in MTS cell proliferation assay contained both PIK3CA E542K and PTEN Loss.

PMID 24088382 · Li et al., 2013 · Open in CIViC

civic

PTEN Loss

Capivasertib + DocetaxelCombination

Predictive

Supports Sensitivity Response

accepted

EID1500

A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the … (full text at CIViC)

PMID 24088382 · Li et al., 2013 · Open in CIViC

civic

PTEN Loss

Docetaxel

Predictive

Supports Resistance

accepted

EID11064

SGC020 was a gastric PDGCX mouse model established from a gastric cancer patient, with a PTEN exon 2-6 gene deletion resulting in undetectable PTEN protein expression. The chemotherapy Taxotere was gi… (full text at CIViC)

PMID 24088382 · Li et al., 2013 · Open in CIViC

civic

Malignant Neoplasm3
PTEN Loss	Buparlisib + Carboplatin + PaclitaxelCombination	Predictive	C	Supports Sensitivity Response	3	accepted	EID714 All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers. PMID 25672916 · Hyman et al., 2015 · Open in CIViC	civic
PTEN Loss	Capivasertib	Predictive	D	Supports Sensitivity Response	3	accepted	EID1502 In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA m… (full text at CIViC) PMID 22294718 · Davies et al., 2012 · Open in CIViC	civic
PTEN Loss	Everolimus	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID5840 In a single-arm, open label phase 2 trial in PIK3CA amplified/mutated and/or PTEN loss encompassing 10 patients, no objective responses were observed but a stable disease response in 4 patients, resul… (full text at CIViC) PMID 28330462 · Kim et al., 2017 · Open in CIViC	civic

Malignant Neoplasm3

PTEN Loss

Buparlisib + Carboplatin + PaclitaxelCombination

Predictive

Supports Sensitivity Response

accepted

EID714

All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers.

PMID 25672916 · Hyman et al., 2015 · Open in CIViC

civic

PTEN Loss

Capivasertib

Predictive

Supports Sensitivity Response

accepted

EID1502

In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA m… (full text at CIViC)

PMID 22294718 · Davies et al., 2012 · Open in CIViC

civic

PTEN Loss

Everolimus

Predictive

Does Not Support Sensitivity Response

accepted

EID5840

In a single-arm, open label phase 2 trial in PIK3CA amplified/mutated and/or PTEN loss encompassing 10 patients, no objective responses were observed but a stable disease response in 4 patients, resul… (full text at CIViC)

PMID 28330462 · Kim et al., 2017 · Open in CIViC

civic

Malignant Ovarian Neoplasm1
PTEN Loss	Cisplatin	Predictive	D	Supports Resistance	2	accepted	EID1492 A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell… (full text at CIViC) PMID 15790433 · Lee et al., 2005 · Open in CIViC	civic

Malignant Ovarian Neoplasm1

PTEN Loss

Cisplatin

Predictive

Supports Resistance

accepted

EID1492

A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell… (full text at CIViC)

PMID 15790433 · Lee et al., 2005 · Open in CIViC

civic

Malignant Prostate Neoplasm3
PTEN Loss	Ipatasertib	Predictive	B	Supports Sensitivity Response	4	submitted	EID8675 Multicenter, international, phase Ib/II trial evaluating ipatasertib 400 mg, ipatasertib 200 mg, or placebo, with abiraterone 1,000 mg orally. Combined blockade with abiraterone and ipatasertib showed… (full text at CIViC) PMID 30037818 · de Bono et al., 2019 · Open in CIViC	civic
PTEN Loss	Ipatasertib	Predictive	B	Supports Sensitivity Response	4	submitted	EID10876 Phase 3 trial compared ipatasertib plus abiraterone and prednisolone or placebo plus abiraterone and prednisolone for patients with castration resistant prostate cancer. Primary endpoint was radiograp… (full text at CIViC) PMID 34246347 · Sweeney et al., 2021 · Open in CIViC	civic
PTEN Loss	Temsirolimus	Predictive	D	Supports Sensitivity Response	4	accepted	EID507 In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779). PMID 11504908 · Neshat et al., 2001 · Open in CIViC	civic

Malignant Prostate Neoplasm3

PTEN Loss

Ipatasertib

Predictive

Supports Sensitivity Response

submitted

EID8675

Multicenter, international, phase Ib/II trial evaluating ipatasertib 400 mg, ipatasertib 200 mg, or placebo, with abiraterone 1,000 mg orally. Combined blockade with abiraterone and ipatasertib showed… (full text at CIViC)

PMID 30037818 · de Bono et al., 2019 · Open in CIViC

civic

PTEN Loss

Ipatasertib

Predictive

Supports Sensitivity Response

submitted

EID10876

Phase 3 trial compared ipatasertib plus abiraterone and prednisolone or placebo plus abiraterone and prednisolone for patients with castration resistant prostate cancer. Primary endpoint was radiograp… (full text at CIViC)

PMID 34246347 · Sweeney et al., 2021 · Open in CIViC

civic

PTEN Loss

Temsirolimus

Predictive

Supports Sensitivity Response

accepted

EID507

In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779).

PMID 11504908 · Neshat et al., 2001 · Open in CIViC

civic

Melanoma2
BRAF V600E AND PTEN Loss	Uprosertib	Predictive	D	Supports Sensitivity Response	2	accepted	EID708 Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B. PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic
BRAF V600E AND PTEN Loss	Dabrafenib + UprosertibCombination	Predictive	D	Supports Sensitivity Response	2	submitted	EID13116 Several BRAF V600E mutant melanoma cell lines (M249, M399, M397AR)) with PTEN mutation or loss of expression were among those sensitive to combination dabrafenib plus AKT inhibitor GSK2141795B, as mea… (full text at CIViC) PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic

Melanoma2

BRAF V600E AND PTEN Loss

Uprosertib

Predictive

Supports Sensitivity Response

accepted

EID708

Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B.

PMID 24735930 · Lassen et al., 2014 · Open in CIViC

civic

BRAF V600E AND PTEN Loss

Dabrafenib + UprosertibCombination

Predictive

Supports Sensitivity Response

submitted

EID13116

Several BRAF V600E mutant melanoma cell lines (M249, M399, M397AR)) with PTEN mutation or loss of expression were among those sensitive to combination dabrafenib plus AKT inhibitor GSK2141795B, as mea… (full text at CIViC)

PMID 24735930 · Lassen et al., 2014 · Open in CIViC

civic

Pancreatic Carcinoma1
PTEN Loss	Akt Inhibitor MK2206	Predictive	C	Supports Sensitivity Response	2	accepted	EID938 Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% … (full text at CIViC) PMID 22025163 · Yap et al., 2011 · Open in CIViC	civic

Pancreatic Carcinoma1

PTEN Loss

Akt Inhibitor MK2206

Predictive

Supports Sensitivity Response

accepted

EID938

Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% … (full text at CIViC)

PMID 22025163 · Yap et al., 2011 · Open in CIViC

civic

Solid Neoplasm1
PTEN Loss	Buparlisib + Carboplatin + PaclitaxelCombination	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID5957 In one arm of this phase 1b study, 7 patients with PTEN deficient tumors were treated with continuous buparlisib (100 mg/daily) orally plus standard dose carboplatin AUC 5 and paclitaxel 175 mg/m2. No… (full text at CIViC) PMID 28281183 · Smyth et al., 2017 · Open in CIViC	civic

Solid Neoplasm1

PTEN Loss

Buparlisib + Carboplatin + PaclitaxelCombination

Predictive

Does Not Support Sensitivity Response

accepted

EID5957

In one arm of this phase 1b study, 7 patients with PTEN deficient tumors were treated with continuous buparlisib (100 mg/daily) orally plus standard dose carboplatin AUC 5 and paclitaxel 175 mg/m2. No… (full text at CIViC)

PMID 28281183 · Smyth et al., 2017 · Open in CIViC

civic

Estrogen Receptor-positive Breast Cancer1unmapped disease
KDM5C Loss-of-function AND ( PIK3CA E545K OR PIK3CA H1047R OR PTEN Loss )	Capivasertib	Predictive	D	Supports Sensitivity Response	3	submitted	EID12936 In ER+ breast cancer cell line models with PI3K-AKT pathway alterations (MCF7 with PIK3CA E545K, T47D with PIK3CA H1047R, CAMA‑1 with PTEN deletion), CRISPR knockout screens identified KDM5C as a modi… (full text at CIViC) PMID 41983950 · Cutano et al., 2026 · Open in CIViC	civic

Estrogen Receptor-positive Breast Cancer1unmapped disease

KDM5C Loss-of-function AND ( PIK3CA E545K OR PIK3CA H1047R OR PTEN Loss )

Capivasertib

Predictive

Supports Sensitivity Response

submitted

EID12936

In ER+ breast cancer cell line models with PI3K-AKT pathway alterations (MCF7 with PIK3CA E545K, T47D with PIK3CA H1047R, CAMA‑1 with PTEN deletion), CRISPR knockout screens identified KDM5C as a modi… (full text at CIViC)

PMID 41983950 · Cutano et al., 2026 · Open in CIViC

civic

Uterus Leiomyosarcoma1unmapped disease
PTEN Loss	Pembrolizumab	Predictive	C	Supports Resistance	3	submitted	EID12145 A treatment-naive patient with uterine leiomyosarcoma was treated with pembrolizumab monotherapy as part of the phase II KEYNOTE-028 trial. The patient showed a near-complete response, with the tumour… (full text at CIViC) PMID 28228279 · George et al., 2017 · Open in CIViC	civic

Uterus Leiomyosarcoma1unmapped disease

PTEN Loss

Pembrolizumab

Predictive

Supports Resistance

submitted

EID12145

A treatment-naive patient with uterine leiomyosarcoma was treated with pembrolizumab monotherapy as part of the phase II KEYNOTE-028 trial. The patient showed a near-complete response, with the tumour… (full text at CIViC)

PMID 28228279 · George et al., 2017 · Open in CIViC

civic

Evidence by cancer (42 items)

Clinical significance (0)